DBV Technologies Stock Up +179% Over the Year, But Technical Threshold Curbs Momentum
DBV Technologies fell to 3.57 euros this Thursday amid a general pullback in European markets. However, the food allergy-focused biotech still shows a remarkable annual performance, with a nearly 180% increase.
In today's session, DBV Technologies dropped by 2.03% to 3.57 euros, after closing at 3.64 euros the previous day. Over the past week, the stock has lost 4.8%, a moderate correction following a quarter of strong gains: the stock rose by 20.4% over three months and has surged by 179.3% over the year. This movement is part of a broader downtrend in the European stock market. The CAC 40 is down by 0.81% during the session, while the SBF 120 has fallen by 0.78%. Sector peers are also affected: Sanofi is down by 0.36% and UCB by 0.78%. Thus, the French biotech is not immune to the selling pressure affecting the entire health sector this Thursday.
Technical Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the stock is currently trading below its 50-day moving average, set at 3.69 euros, indicating a slight slowdown in the short-term bullish momentum. However, the price remains well above the 200-day moving average (2.63 euros), confirming the strong upward trend observed over the past year. The Relative Strength Index (RSI), which measures the intensity of recent movements, is at 52, indicating a perfectly neutral territory, far from overbought or oversold zones. The stock is also oscillating within its Bollinger Bands, between the lower bound at 3.22 euros and the upper bound at 3.89 euros. The nearest support is at 3.37 euros, while resistance is found at 4.04 euros, a level that would be a key threshold if the upward momentum resumes.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
